Patients' acceptance of the deltoid application of risperidone long-acting injection

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
Stephan HeresWerner Kissling

Abstract

Recently risperidone long-acting injection (RLAI) was approved for alternative injection into the deltoid muscle in addition to the already established injection into the gluteal muscle. For the first time two different injection locations of a long-acting antipsychotic injection can be offered to patients. Their actual acceptance is of key interest. We surveyed 60 patients stabilized on gluteal RLAI therapy in our depot outpatient clinic. Participants were offered the possibility of switching to the alternative deltoid injection in a standardized manner. Prior to switching patients scored the extent of perceived pain and experienced level of shame through the present gluteal injection therapy on a 7-point-scale. Patients choosing to switch were followed up after three months and asked to report on their individual experience. Switching to the deltoid application was chosen by 34 out of 60 patients. Three months later 15 patients were still receiving deltoid injections. The main reason for their staying with the deltoid injection was improved practicability as reported by these patients and 13 out of 15 patients clearly preferred the new location over the gluteal application. The main reason for returning to the gluteal injecti...Continue Reading

References

May 1, 1994·Drugs·J M DavisL ] Metalon L [corrected to Matalon
Oct 3, 2001·The British Journal of Psychiatry : the Journal of Mental Science·C E AdamsA S David
Mar 13, 2002·The Australian and New Zealand Journal of Mental Health Nursing·D Rock
Mar 3, 2004·Human Psychopharmacology·Kang SimChay Hoon Tan
Mar 16, 2007·Acta Psychiatrica Scandinavica·H A Nasrallah
Aug 11, 2007·International Clinical Psychopharmacology·Stephan HeresFrank-Gerald Pajonk
Nov 8, 2007·Health Expectations : an International Journal of Public Participation in Health Care and Health Policy·Johannes HamannMartin Härter
Feb 2, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Jeonghoon AhnLizheng Shi
Jun 28, 2008·Journal of Psychopharmacology·M X PatelA David
Jun 2, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·David HoughMarielle Eerdekens
Mar 3, 2011·The American Journal of Psychiatry·Jari TiihonenPasi Korhonen

❮ Previous
Next ❯

Citations

Jan 22, 2020·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Hiroyuki KameiNakao Iwata
Feb 17, 2017·The International Journal of Neuropsychopharmacology·Arash RaoufiniaFrank Larsen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Progress in Neuro-psychopharmacology & Biological Psychiatry
Stephan HeresWerner Kissling
European Psychiatry : the Journal of the Association of European Psychiatrists
Stephan HeresWerner Kissling
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
Johannes HamannWerner Kissling
© 2021 Meta ULC. All rights reserved